RxDoctor Payments Data

Paul Madaj, MD

Clinical Cardiac Electrophysiology · Springfield, MANPI 1679994396

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (42.1%), grants and travel and lodging — rather than concentrated in one kind of arrangement. 46 manufacturers reported payments, led by Medtronic at 42.5% of the total. Reporting peaked in 2023 at $25,889 and has fallen 83.9% since, to $4,164 in 2025.

$60,741in general payments, 2019–2025

Across 809 payments — averaging $75.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$26K
  • Biotronik Inc.$10K
  • Abbott$6K
  • Boston Scientific$6K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$3K
  • Johnson & Johnson$1K
  • plus $9K from 40 others

What the payments were for

  • Speaking & faculty fees$1,5002%
  • Grants$22,54237%
  • Travel & lodging$8,84115%
  • Food & beverage$25,57642%
  • Education$2,1654%
  • Entertainment$1170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$60,741 in reported general payments places this provider in the 75th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

See all clinical cardiac electrophysiology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$292,895
Medicare patients
1,765
Services billed
3,457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban65$81,254
Metoprolol Succinate66$906
Diltiazem 24hr Er (Cd)Diltiazem Hcl16$521
Amiodarone Hcl14$311
Carvedilol14$126
Metoprolol Tartrate11$107
Amlodipine Besylate12$58
Cephalexin14$43

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$690$81,25465 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 106 clinical cardiac electrophysiology providers in Massachusetts.

Other clinical cardiac electrophysiology in Springfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →